Published in Hepatitis Weekly, September 21st, 1998
The named companies are among several currently engaged in programs for the development of hepatitis C virus (HCV) protease inhibitor drugs which fall within the scope of Chiron's HCV protease patents, according to Chiron.
Chiron said it has continued to make its patent estate available to companies working to discover drugs for the treatment of HCV infection while at the same time...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.